KYMR (STOCKS)
Kymera Therapeutics, Inc. Common Stock
$88.530000
+3.480000 (+4.09%)
Prev close: $85.050000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Nello Mainolfi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,222.90M
- Employees
- 225
- P/E (TTM)
- -23.12
- P/B (TTM)
- 4.38
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
16
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.97 | $-0.81 | -0.1578 | -19.43% |
|
Sep 2025 (Q3)
|
$-0.94 | $-0.82 | -0.1200 | -14.63% |
|
Jun 2025 (Q2)
|
$-0.95 | $-0.83 | -0.1238 | -14.98% |
|
Mar 2025 (Q1)
|
$-0.82 | $-0.93 | +0.1146 | +12.26% |
Financial Statements
| Revenues | $39.21M |
| Benefits Costs and Expenses | $350.56M |
| Cost Of Revenue | $39.21M |
| Costs And Expenses | $350.56M |
| Gross Profit | $0.00 |
| Operating Expenses | $388.61M |
| Research and Development | $316.57M |
| Other Operating Expenses | $72.04M |
| Operating Income/Loss | -$349.40M |
| Income/Loss From Continuing Operations After Tax | -$311.35M |
| Income/Loss From Continuing Operations Before Tax | -$311.35M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$311.35M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$311.35M |
| Net Income/Loss Available To Common Stockholders, Basic | -$311.35M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.69 |
| Diluted Earnings Per Share | -$3.69 |
| Basic Average Shares | 84,490,585 |
| Diluted Average Shares | 84,490,585 |
| Assets | $1.74B |
| Current Assets | $871.21M |
| Noncurrent Assets | $871.60M |
| Fixed Assets | $43.18M |
| Other Non-current Assets | $828.42M |
| Liabilities | $163.15M |
| Current Liabilities | $83.21M |
| Accounts Payable | $4.02M |
| Other Current Liabilities | $79.20M |
| Noncurrent Liabilities | $79.94M |
| Equity | $1.58B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.58B |
| Liabilities And Equity | $1.74B |
| Net Cash Flow From Operating Activities | -$232.89M |
| Net Cash Flow From Operating Activities, Continuing | -$232.89M |
| Net Cash Flow From Investing Activities | -$521.06M |
| Net Cash Flow From Investing Activities, Continuing | -$521.06M |
| Net Cash Flow From Financing Activities | $990.71M |
| Net Cash Flow From Financing Activities, Continuing | $990.71M |
| Net Cash Flow | $236.76M |
| Net Cash Flow, Continuing | $236.76M |
| Comprehensive Income/Loss | -$308.07M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$308.07M |
| Other Comprehensive Income/Loss | $3.29M |